March 10, 2020 / 7:52 AM / in 21 days

BRIEF-Cantargia Acquires Cellerant IP On IL1RAP

March 10 (Reuters) - Cantargia AB:

* CANTARGIA ACQUIRES CELLERANT IP ON IL1RAP

* ACQUIRED IP INCLUDES A US PATENT ON IL1RAP AS A TARGET FOR ANTIBODY THERAPY IN LEUKEMIA

* ACQUISITION OF PATENT PORTFOLIO FROM CELLERANT THERAPEUTICS INC COVERING ASPECTS AROUND INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN (IL1RAP)

* CELLERANT TO RECEIVE INSIGNIFICANT UPFRONT PURCHASE PAYMENT, WILL BE ENTITLED TO LOW SINGLE DIGIT ROYALTY ON SALES COVERED BY CLAIMS IN ACQUIRED CELLERANT PATENTS, UNTIL THEY EXPIRE

* NO OTHER MILESTONE PAYMENT IS INCLUDED IN AGREEMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below